Olutasidenib | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Olutasidenib
US Patents

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

Contact Supplier

Inke S.A: APIs manufacturing plant.

Contact Supplier

xyz-pharma-2025-04-21

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

With Fermion, start the journey of your innovative API.

Contact Supplier

Send me more info on How To Grow My Business Digitally?

Olutasidenib

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

16 Drugs in Development

16 Drugs in Development

FINISHED DOSAGE FORMULATIONS

1 FDF Dossiers, 1 FDA Orange Book

1 FDF Dossiers
1 FDA Orange Book

DIGITAL CONTENT

19 News #PharmaBuzz

19 News #PharmaBuzz

PATENTS & EXCLUSIVITIES

13 US Patents, 2 US Exclusivities

13 US Patents
2 US Exclusivities

Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

13 All

01 13RIGEL PHARMS

filter Patent Number Reset all filters

13 All

01 19834539

02 110414752

03 110532047

04 110550098

05 110959994

06 111013733

07 111013734

08 111376246

09 111497743

10 111498913

11 111723905

12 111738018

13 112053463

filter API Patent Reset all filters

13 All

01 3Y

02 10Blank

filter FDF Patent Reset all filters

13 All

01 7Y

02 6Blank

filter Expiration Date Reset all filters

13 All

01 42035-09-18

02 72039-05-16

03 12039-07-17

04 12039-11-12

Product Main Page

01

RIGEL PHARMS

Iran Expo

Not Confirmed

RIGEL PHARMS

Country

Iran Expo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2039-05-16

OLUTASIDENIB

US Patent Number : 11497743

Drug Substance Claim :

Drug Product Claim :

Application Number : 215814

Patent Use Code : U-3495

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-05-16

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

02

RIGEL PHARMS

Iran Expo

Not Confirmed

RIGEL PHARMS

Country

Iran Expo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2039-05-16

OLUTASIDENIB

US Patent Number : 11376246

Drug Substance Claim :

Drug Product Claim :

Application Number : 215814

Patent Use Code : U-3495

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-05-16

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

03

RIGEL PHARMS

Iran Expo

Not Confirmed

RIGEL PHARMS

Country

Iran Expo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2039-05-16

OLUTASIDENIB

US Patent Number : 11013734

Drug Substance Claim :

Drug Product Claim :

Application Number : 215814

Patent Use Code : U-3495

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-05-16

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

RIGEL PHARMS

Iran Expo

Not Confirmed

RIGEL PHARMS

Country

Iran Expo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2039-05-16

OLUTASIDENIB

US Patent Number : 11013733

Drug Substance Claim :

Drug Product Claim :

Application Number : 215814

Patent Use Code : U-3496

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-05-16

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

RIGEL PHARMS

Iran Expo

Not Confirmed

RIGEL PHARMS

Country

Iran Expo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2035-09-18

OLUTASIDENIB

US Patent Number : 9834539

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 215814

Patent Use Code : U-3497

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-09-18

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

RIGEL PHARMS

Iran Expo

Not Confirmed

RIGEL PHARMS

Country

Iran Expo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2039-07-17

OLUTASIDENIB

US Patent Number : 11738018

Drug Substance Claim :

Drug Product Claim :

Application Number : 215814

Patent Use Code : U-3684

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-07-17

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

07

RIGEL PHARMS

Iran Expo

Not Confirmed

RIGEL PHARMS

Country

Iran Expo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2039-05-16

OLUTASIDENIB

US Patent Number : 10532047

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 215814

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-05-16

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

08

RIGEL PHARMS

Iran Expo

Not Confirmed

RIGEL PHARMS

Country

Iran Expo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2039-05-16

OLUTASIDENIB

US Patent Number : 12053463

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 215814

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-05-16

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

09

RIGEL PHARMS

Iran Expo

Not Confirmed

RIGEL PHARMS

Country

Iran Expo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2039-05-16

OLUTASIDENIB

US Patent Number : 10959994

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 215814

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-05-16

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

10

RIGEL PHARMS

Iran Expo

Not Confirmed

RIGEL PHARMS

Country

Iran Expo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2035-09-18

OLUTASIDENIB

US Patent Number : 10414752

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 215814

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-09-18

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

1
2

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!